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Poster Session-I 47weight, a T cell dose comparable to bone marrow transplant, in
a complete product with the exception of incidental losses that occur
during the process of T cell depletion (TCD). Following collection,
CD31T cells are enumerated by flow cytometry and a portion of the
product containing a dose of 3.0  107 CD31 cells/kg is set aside.
The remainder of the product is depleted of T cells by a two-step
method where the cells are first labeled with the anti-CD3monoclo-
nal antibody OKT3 attached to ferromagnetic microspheres. The
product is then incubated for 30min, washed twice, and passed
through a magnetized bead matrix that isolates the CD31 T cells
(CliniMACS; Miltenyi Biotec, Duarte CA). The T cell depleted
product is then combined with the set aside portion of the product
containing 3.0  107 CD31 cells/kg for the transplant. Three sepa-
rate procedures revealed 3.2 6 0.7 log TCD for the depleted prod-
uct. Recovery of other cellular components in the TCD product was
as follows: B cells 75.4% 6 17.5, NK cells 33.9% 6 30.3, CD346
cells 42.0% 6 8.0. Viability of the TCD product was 97.1% 6 1.9
and sterility assessment revealed all cultures to be free of organisms
following 14 days culture. Taken together, these data confirm
that partial TCD can be accomplished in a closed system allowing
standardization of graft T cell content.120
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Background: Stem cell dose has been shown to be important for
outcome in patients who undergo stem cell transplantation (SCT).
Grafts may contain varying amounts of different cell populations like
CD31, CD191, CD561, CD41 and CD81 immunocompetent
cells, whose role for clinical outcome is less clear.
Patients and Methods: We analyzed 591 patients who under-
went SCT at Karolinska University Hospital, Huddinge between
1998 to 2007 and correlated FACS results of the above mentioned
cell populations to clinical outcome. Most patients (76%) had he-
matological malignancies. 58% of the patients received a myeloa-
blative conditioning regimen, 62% were given peripheral blood
stem cells (PBSC) and in 58% of the transplants an unrelated donor
was used.
Results: As expected, PBSC contained much higher levels of all
different cell populations as compared to BM. We found that pa-
tients reciving high numbers of CD41, and CD81 cells had signif-
icantly more rapid engraftment. Also, a CD41 level above 200 
10(6)/kg was correlated to higher risk of developing acute GVHD
grades II-IV (41%) as compared to patients receiving below this level
(24%) (p\0,037).While the incidence of bacteria sepsis was lower in
patients receiving a high number of cell dose (CD3, CD19, CD56),
no correlation between cell dose and CMV reactivation was found.
Relapse free- and overall survivals were not significantly affected
by the different cell populations.
Conclusion: Grafts containing high numbers of CD41 cells is
a risk factor for developing severe acute GVHD but survival rates
were not significantly correlated to graft composition.HEMATOPOIESIS/MESENCHYMAL CELLS
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Multipotent mesenchymal stromal cells (MSC) are increasingly
used to treat refractory graft-versus-host-disease and other com-
plications in HLA-matched and mismatched hematopoietic stem
cell transplantation (HSCT) patients. We evaluated immunoge-nicity of human allogeneic MSC infused post-transplant to
HLA-mismatched, i.e. patients undergoing HSCT.We compared
recipient lymphocyte response to MSC and peripheral blood lym-
phocytes (PBL) from theMSC or third party donors before and af-
ter infusion, and lymphocyte responses to MSC and to PBL from
the MSC donor in primary and secondary challenge using 3H-ty-
midine. MSC recipients displayed in median responses less than
500 counts per minute (CPM) to infused third party MSC 1
week to 6 months following infusion. However, the recipients re-
sponded normally to MSC donor lymphocytes, .1000 CPM
(p\0.005), and third party lymphocytes, .5000 CPM
(p\0.005). MSC failed to prime responder lymphocytes to rechal-
lenge with PBL, as the responses was \10 000 versus .30 000
CPM for the corresponding control (p\0.05). On MSC rechal-
lenge of lymphocytes primed with PBL from the MSC donor,
only responses\500 CPM occurred. MSC upregulated lympho-
cyte gene expression of CD25, IFN-g, FoxP3, CTLA-4 and IL-
10 upon MSC/PBL co-culture and MSC presence in mixed
lymphocyte cultures. Unprimed and primed responder lympho-
cytes expanded and proliferated poorly to MSC as stimuli, evalu-
ated by flow cytometry. The MSC failed to induce CD251
(activated) or CD571 (effector) CD41 or CD81 subsets and
only inconsistently induced FoxP31 regulatory T lymphocytes.
These results confirm in vivo and in vitro that infused MSC are
weakly immunogenic and do not induce significant immunological
memory in HLA-disparate recipients.122
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Delayed or failed engraftment is a frequent complication of CBT.
We developed an approach that involves ex vivo co-culture of CB
mononuclear cells with third party marrow derived MSCs. Patients
must have 2 CB units matched in at least 4/6 HLA antigens, with
a minimum of 1 107 TNC/Kg per unit. A family member matched
in at least 2/6 antigens or more serves as the marrow-derived MSC
donor.
Methods: Diagnoses: AML/MDS (N 5 4), ALL (N 5 1), and
CLL (N5 1).One patientwas inCR and 5 had active disease (1 failed
a previous CBT). Preparative regimen: myeloablative melphalan
(140mg/m2), thiotepa (10mg/kg), fludarabine (160mg/m2), and rab-
bit ATG (3 mg/kg). GVHD prophylaxis: tacrolimus and MMF.
Median weight was 57 Kg (range, 14–79). Donor-recipient HLA
matching was 5 of 6 in 35% of the cases and 4 of 6 in 65%. Ex-
vivo EXP: 100 ml of marrow was aspirated from the family donor
and MSCs were generated in 10 T175 flasks. The CB unit with
the lowest TNC dose was thawed, and placed into flasks containing
confluent layers of MSCs in EXP media with SCF, FLT3, G-CSF
and TPO. After 7 days at 37C, the non-adherent cells were re-
moved, and placed into one-liter Teflon-coated culture bags and cul-
tured for an additional 7 days (14 days total); 50 ml of media/growth
factors was added to the flasks to culture the remaining adherent
layer during that time period. On day 14 the cells were washed and
infused along with a 2nd unmanipulated unit.
Results: There were no toxicities attributable to EXP. The me-
dian fold EXP was 12 (1–13) for TNC and 12 (0–27) for CD341
cells. Median time to neutrophil and platelet engraftment was
14.5 days (12–23) and 31 days (25–51). All patients (n 5 6)
engrafted neutrophils and platelets and became complete donor(s)
chimeras. Chimerism: 1 unit dominated in all patients; 2 patients
have mixed donors chimerism 4 months after CBT, with 5%
and 20% of the EXP unit contributing to hemopoiesis. Three pa-
tients had no evidence of EXP unit-derived hemopoiesis after day
130, while 1 patient is 100% donor but the contributing unit
